CAB-ROR2-ADC
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CAB-ROR2-ADC, covering 2025-01-15 to 2025-01-15. Get the full timeline:
Most recent: Clinical Trial Update: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) [Phase 1, Phase 2]